Intellectual Property India Publishes Patent Application for 'Long-Acting Parathyroid Hormone Receptor Agonist Fusion Protein And Use Thereof' Filed by Shanghai Btd-Bio Technology Co. Ltd.

MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202647043737 A) filed by Shanghai Btd-Bio Technology Co. Ltd., Shanghai, on April 6, for 'long-acting parathyroid hormone receptor agonist fusion protein and use thereof.'

Inventor(s) include Song, Liping; Zhang, Huanhuan; Huang, Xiaohui; Mu, Jun; Xu, Hong; Fan, Yi; and Wang, Hongyan.

The application for the patent was published on April 17, under issue no. 16/2026.

According to the abstract released by the Intellectual Property India: "A long-acting parathyroid hormone receptor agonist fusion protein and the use thereof. The fusion protein can inhibit the activity of RANKL and promote PTHR-mediated bone anabolism, and contains a first arm and a second arm. The first arm contains a functional region targeting RANKL and an Fc region, and the second arm contains a functional region capable of activating PTHR and an Fc region. The long-acting parathyroid hormone receptor agonist fusion protein has multiple advantages, e.g., better drug efficacy, longer lasting effect, better safety, higher structural stability and higher expression level, and the overall performance thereof is superior to that of an existing or potential treatment means, e.g., teriparatide, PEG-PTH, anti-RANKL monoclonal antibody, romosozumab, or the control sample synPTH-aRANKL-1."

The patent application was internationally filed on Sept. 11, 2024, under International application No.PCT/CN2024/118317.

Disclaimer: Curated by HT Syndication.